GlassScriptPhysician profile
Bailey Slater Ford
NPI 1518322650
$4,896.12
in general payments reported to CMS, 2019-2025
28 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,378 · 2022: $1,260 · 2023: $1,108 · 2024: $662 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,257.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $808.94 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $643.13 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $488.75 | 2021-2025 | Rybelsus, Ozempic |
| Amgen INC. | $463.21 | 2021-2024 | Otezla, Repatha, Evenity |
| Abbvie INC. | $365.81 | 2021-2025 | |
| Pfizer INC. | $282.35 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.25 | 2021-2022 | |
| Astellas Pharma US INC | $207.40 | 2021-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $207.06 | 2021-2022 | |
| Glaxosmithkline, LLC. | $172.35 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $171.45 | 2021-2023 | |
| Abbott Laboratories | $149.34 | 2021-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $149.12 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.27 | 2023-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $79.47 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.93 | 2022-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $53.56 | 2021-2022 | |
| Axsome Therapeutics, INC. | $32.82 | 2023 | Auvelity |
| Horizon Therapeutics Plc | $29.01 | 2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $27.29 | 2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $24.16 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.15 | 2025 | Xifaxan |
| Mylan Specialty L.P. | $22.61 | 2021 | |
| Exact Sciences Corporation | $21.08 | 2024 | Cologuard Collection Kit |
| Eisai INC. | $20.09 | 2021 | |
| International Rehabilitative Sciences, INC | $13.66 | 2024 | Rs 4i Plus Sequential Stimulator |
| Tactile Systems Technology INC | $12.57 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bailey Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.